First treatment for rare genetic condition
29 April 2014 | By BioMarin
The first and only drug designed to address Morquio A syndrome is now available in Europe and the UK for children and adults with this rare genetic condition...
List view / Grid view
News
Gilead’s sovaldi® demonstrates efficacy and safety among chronic hepatitis C patients with advanced liver disease
29 April 2014 | By Gilead
Gilead Sciences, Inc. announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi® (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus...
Biogen Idec to present new two-year data from the plegridy™ (peginterferon beta-1a) phase 3 advance study at AAN Annual Meeting
29 April 2014 | By Biogen Idec
Biogen Idec announced two-year data from its Phase 3 ADVANCE clinical trial for PLEGRIDY™ (peginterferon beta-1a) in people with relapsing forms of multiple sclerosis...
2013 annual report on EudraVigilance: over 1 million adverse reaction reports received and processed
29 April 2014 | By The European Medicines Agency
In 2013, EudraVigilance received more than one million post-marketing expedited adverse-drug-reaction reports...
GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD
29 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Commission has granted marketing authorisation for Incruse® (umeclidinium)...
Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis
28 April 2014 | By Roche
First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy...
Teva and OncoGenex announce top-line survival results of Phase III SYNERGY trial evaluating custirsen in combination with first-line docetaxel and prednisone for metastatic castrate-resistant prostate cancer
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...
GSK and MMV announce start of phase III programme of tafenoquine for Plasmodium vivax malaria
28 April 2014 | By GlaxoSmithKline
GlaxoSmithKline and Medicines for Malaria Venture announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine...
Pfizer confirms prior discussions with AstraZeneca regarding a possible combination and its continuing interest in a possible merger transaction
28 April 2014 | By Pfizer
This is an announcement of a possible offer falling under Rule 2.4 of the City Code on Takeovers and Mergers (the “Code”)...
FDA approves Roche’s HPV test for first-line primary screening for Cervical Cancer
25 April 2014 | By Roche
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older...
Daiichi Sankyo announces discontinuation of phase 3 clinical trial in Japan of nimotuzumab (DE-766) in Lung Cancer
25 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the discontinuation of the phase 3 clinical trial conducted in Japan for nimotuzumab (DE-766) in Lung Cancer...
Announcement regarding the post-evaluation result for the project of H5N1 influenza vaccine
25 April 2014 | By Daiichi Sankyo
Kitasato Daiichi Sankyo Vaccine engaged in preparations to build a scheme to supply vaccines by the end of March 2014...
Pride-HD study enrolling patients globally to further evaluate pridopidine for the symptomatic treatment of Huntington’s Disease
25 April 2014 | By Teva
Study initiation represents significant milestone for patients with a disease with limited effective treatment options...
Novartis’ INSTEAD study for Onbrez® Breezhaler® in patients with moderate COPD meets primary objective
25 April 2014 | By Novartis
Novartis announced top-line results from the Phase IV INSTEAD switch study in patients with chronic obstructive pulmonary disease, which met its primary objective...
Hydra Biosciences and Boehringer Ingelheim announce worldwide collaboration to develop small-molecule inhibitors for the treatment of central nervous system diseases and disorders
24 April 2014 | By Boehringer Ingelheim
Hydra Biosciences, Inc. and Boehringer Ingelheim jointly announced that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors...
